Other

Mtm Laboratories, Ag

Zyagnum Ag

Tavargenix Gmbh

Roche Mtm Laboratories Ag

Coy, Johannes

Coy, Johannes, Dr.

Johannes Coy

Rainer Hipfel

Birgit Wasser

Annemarie Poustka

Ralf Schierl

The invention relates to the use of at least one inhibitory structural analog or inhibitory functional analog of a coenzyme (such as thiamine for example) of an enzyme group, the enzyme members of which catalyze anabolic and/or catabolic and/or energy-releasing metabolic reactions that are of essential significance for the functionality of the overall metabolism of cells, in particular mammalian cells. The invention is used to treat patients in order to produce a general successive (in particular also continuous) slowing down of the metabolic processes of endogenous cells and exogenous cells in the body of the patient and thus achieve a slowing down of disease-causing processes in particular.

Use of co-enzyme antagonists to slow metabolism

The method for qualitative and qualitative detecting of the extend of use and the correct process flow of the mammalian aerobic glucose fermentation metabolic pathway (mam-aGF) in a mammalian individual is characterized in that the enzyme TKTL1 is used as indicator and target molecule and the structural and/or functional parameter of said TKTL1 in a biological sample of said individual (patient) are taken as indication for the qualitative and qualitative run of the mam-aGF in the cells and/or tissue of said individual (patient). In combination with the use of inhibitors and activators of the mam-aGF the method is further suitable for checking and controlling the mam-aGF in an individual (patient).

Method for checking and controlling the mammalian lactic acid fermentation process/aerobic glucose fermentation metabolic pathway in mammalian organism

The method for qualitative and quantitative detecting of the extend of use and the correct process flow of the mammalian aerobic glucose fermentation metabolic pathway (mam-aGF) in a mammalian individual is characterized in that the enzyme TKTL1 is used as indicator and target molecule and the structural and/or functional parameter of said TKTL1 in a biological sample of said individual (patient) are taken as indication for the qualitative and quantitative run of the mam-aGF in the cells and/or tissue of said individual (patient). In combination with the use of inhibitors and activators of the mam-aGF the method is further suitable for checking and controlling the mam-aGF in an individual (patient).

Disclosed is a beverage and a method of administering the beverage. The beverage is free of phosphoric acid and instead contains at least 0.3% by weight/volume of gluconic acid, is low in minerals, specifically contains less than 250 mg/liter of minerals, is low in sugar, specifically contains at most 2.5% by weight/volume of sugar. These sugars comprise at least 10% weight/weight galactose and in addition a proportion of isomaltulose and/or tagatose The beverage has a glycemic index of at most 35 (GI&#x3c;35).

Refreshing beverage

The invention provides a novel chocolate mass which has a glycemic index of less than 29 (GI&#x3c;29) and of which the content of added sugar comprises at least 10% galactose and in addition a content of iosmaltulose and/or tagatose. The chocolate mass additionally has a content of vitamin E in the form of a tocotrienol-tocopherol mixture from natural sources, wherein the content of tocotrienols in the chocolate mass is greater than the content of tocopherols.

Chocolate mass

The invention relates to an automatable method for the identification, quantification and discrimination of specific signals in relation to non-specific signals in detection methods by means of a detector emitting or generating signals, in which at least one control approach is carried out in parallel to the actual test approach, which contains all the components of the actual test approach but in which the binding domain(s) of the detector is/are blocked. The analytical measurements of the signals of the control approach and of the actual test approach are compared with each other and the signal of the specifically bound detector in the test approach is calculated therefrom.

Automatable method for the identification, quantification and discrimination of specific signals in relation to non-specific signals in detection methods by means of a detector

The invention relates to a novel sweet-tasting refreshing beverage, which is free of phosphoric acid and instead contains at least 0.3% by weight/volume of gluconic acid, which is low in minerals, specifically contains less than 250 mg/liter of minerals, which is low in sugar, specifically contains at most 2.5% by weight/volume of sugar, wherein these sugars comprise at least 10% weight/weight galactose and in addition a proportion of isomaltulose and/or tagatose, and which has a glycemic index of at most 35 (GI&#x3c;35).

The present invention relates to compounds and methods for detection and treatment of carcinomas and their precursor lesions. The invention provides DNase nucleic acids and polypeptides useful for the detection and treatment of carcinomas and their precursor lesions. The invention is more specifically related to a method for detection of carcinomas and their precursor lesions comprising the detection of the level and/or the subcellular localization of one or more DNase molecules in biological samples. Furthermore the present invention provides methods for early diagnosis, prognosis and monitoring of the disease course of carcinomas and their precursor lesions as well as for the treatment of said lesions.

Compounds and methods for detection of carcinomas and their precursor lesions

Methods for in vitro diagnosis of carcinoma are disclosed. In one aspect the invention relates to methods such as detecting the level of transketolase like-1 polypeptide, which are especially useful for the detection of tumors and their precursory stages based on the detection of overexpression of human transketolase like-1 gene in biological samples. In another aspect the invention relates to methods for treatment of disorders associated with the overexpression of human transketolase like-1 gene. Methods for treatment may include gene therapeutic approaches as well as methods for inhibiting or reducing the activity of transketolase like-1 polypeptides.

Compositions and methods for detection and treatment of proliferative abnormalities associated with overexpression of human transketolase like-1 gene

The present invention relates to nucleic acids and polypeptides associated with lung cancer. The invention is more specifically related to a nucleic acids and the polypeptides transcribed thereof, the expression of which is significantly altered in association with lung cancer. The invention relates to a series of differentially spliced transcripts of the gene disclosed herein, that are associated with tumors of the respiratory tract. Furthermore the present invention provides a method for early diagnosis, prognosis and monitoring of the disease course and for therapy and vaccination of cell proliferative disorders such as e.g. lung tumors.

Marker molecules associated with lung tumors

The method for qualitative and quantitative detecting of the extend of use and the correct process flow of the mammalian aerobic glucose fermentation metabolic pathway (mam-aGF) in a mammalian individual is characterized in that the enzyme TKTL1 is used as indicator and target molecule and that the structural and/or functional parameter of said TKTL1 in a biological sample of said individual (patient) are taken as indication for the qualitative and quantitative run of the mam-aGF in the cells and/or tissue of said individual (patient). In combination with the use of inhibitors and activators of that mam-aGF the method is further suitable for checking and controlling the mam-aGF in an individual (patient).

Method for checking and controlling the mammalian lactic acid fermentation process / aerobic glucose fermentation metabolic pathway in mammalian organism

The present invention relates to methods for treatment and diagnosis of disorders associated with abnormally proliferating cells. In one aspect the invention relates to methods, which are especially useful for the detection of tumors and their precursory stages based on the detection of overexpression of human transketolase like-1 gene in biological samples. In another aspect the invention relates to methods for treatment of disorders associated with the overexpression of human transketolase like-1 gene. Methods for treatment may include gene therapeutic approaches as well as methods for inhibiting or reducing the activity of transketolase like-1 polypeptides.

Growing community of inventors

Hainburg, Germany

Johannes Coy